19 April 2024
Clifford Chance advises SciClone Pharmaceuticals on proposed HK$8.79 billion privatisation by GL Capital
Advising firms
Deal team
6 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Christine Xu Lead | Clifford Chance | Partner | Not stated | Not stated |
| Tommy Tam Lead | Clifford Chance | Partner | Not stated | Not stated |
| Samson Chan | Clifford Chance | Counsel | Not stated | Not stated |
| Anson Wong | Clifford Chance | Associate | Not stated | Not stated |
| Charmaine Lee | Clifford Chance | Associate | Not stated | Not stated |
| Alice Tsui | Clifford Chance | Trainee | Not stated | Not stated |
3 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 1.12bn (approximately US$1.12 billion)
- What the figure measures
- Total transaction value
- Client
- SciClone Pharmaceuticals (Holdings) LimitedTarget
- Counterparties
- GL Capital (Buy-side)